Psychedelic · TRP-8803

TRP-8803 (IV-infused psilocin)

Proprietary intravenous infusion formulation of psilocin, the active metabolite of psilocybin, developed by Entropy Neurodynamics (formerly Tryptamine Therapeutics / Tryp Therapeutics) for use alongside psychotherapy. Delivering psilocin directly into the bloodstream avoids gastrointestinal absorption and conversion of psilocybin, which the sponsor says gives a rapid onset (about 15-20 minutes), a controllable depth and duration of the psychedelic state, and the ability to pause or stop the infusion. Psilocin acts as a serotonin 5-HT2A receptor agonist. In a Swinburne University open-label study in treatment-resistant binge eating disorder, the sponsor reported that all six Cohort 1 patients achieved clinically meaningful improvement and three of six had no binge-eating episodes over 12 weeks after two infusions. A 72-patient, eight-indication basket study received ethics approval in August 2026.

Also known as: TRP-8803, TRP 8803, TRP8803, psilocin besylate

Key facts

Modality
Psychedelic
Chemical class
tryptamine
Chemistry
Achiral
Mechanism
5-HT2A agonist
Highest phase
Phase 1
Lead indication
Binge eating disorder
Trials
4 tracked
Next catalyst
By end of 2026 (Q4 CY2026) — Topline data (Binge eating disorder)

Mechanism of action#

TRP-8803 delivers psilocin, the pharmacologically active metabolite of psilocybin, by controlled intravenous infusion. Psilocin is a serotonin 5-HT2A receptor agonist; the sponsor links this to cortical network reorganisation, increased brain entropy and enhanced neuroplasticity. IV delivery is intended to remove the variable absorption and dephosphorylation of oral psilocybin so that onset, depth and duration of the psychedelic state can be titrated and the infusion stopped if needed.

TargetActionAffinity
5-HT2AprimaryHTR2AAgonist—ⓘ

Formulations#

FormulationRouteRegimenPharmacokinetics
TRP-8803 intravenous psilocin infusioncontrolled IV infusion (loading dose + maintenance infusion)
BED study Cohort 1: 10 mg psilocin per session, as a 5 mg loading dose over 20 minutes followed by a 5 mg maintenance dose over 120 minutes (140 minutes total), two sessions two weeks apart with supportive psychotherapy. Cohort 2: shortened 60-minute regimen (20-minute loading + 40-minute maintenance), selected by the DSMB; the Cohort 2 dose has not been disclosed.
Intravenous——

Development timeline#

Jul 24Jan 25Jul 25Jan 26Jul 26TodayPhase 131 Dec 2026 — upcoming — Cohort 2 topline (n=6, shortened 60-minute TRP-8803 infusion regimen) and final BED study results, expected by the end of calendar 2026.10 Oct 2026 — Conference presentation — Two TRP-8803 BED posters at the 39th ECNP Congress, Munich15 Sept 2026 — readout (met) — Cohort 1 12-week durability: all six patients kept a clinically meaningful improvement; 3/6 had no binge-eating episodes across the 84-day follow-up; weekly binge episodes 73% below baseline; anxiety -50%, depression -42%, quality of life +61%.4 Aug 2026 — Partnership — HREC approval and new Swinburne research agreement for 72-patient, eight-indication TRP-8803 basket study1 Aug 2026 — Partnership — Pre-Clinical Trial Agreement with UCSF for a proposed US Phase 2 of TRP-8803 vs escitalopram in MDD20 Jul 2026 — Patent granted — South African patent granted for psilocybin-based treatment of fibromyalgia10 Jul 2026 — Patent granted — Australian patent granted for psilocin crystalline forms7 Jul 2026 — readout (met) — Cohort 1 topline (n=6, 140-minute regimen): 100% clinically meaningful improvement (>=30% from baseline), 50% (3/6) complete remission (zero binge episodes in the 4 weeks after treatment), 74% reduction in weekly binge-eating episodes, GAD-7 -58%, PHQ-9 -57%.1 Jul 2026 — Partnership — GMP manufacturing agreement with BioCina for TRP-88031 Nov 2025 — Corporate rebrand / name change — Tryptamine Therapeutics renamed Entropy Neurodynamics; ASX code TYP becomes ENP14 Oct 2025 — phase change — First patient enrolled at Swinburne University and a 4-week baseline assessment begun. The trial will recruit 12 BED patients in two cohorts, each given two TRP-8803 doses 14 days apart with supportive therapy.14 Oct 2025 — Trial started — First patient enrolled in TRP-8803 binge eating disorder trial17 Apr 2025 — phase change — BED-IV study registered on ANZCTR (ACTRN12625000330448), sponsor Tryptamine Therapeutics: 'A Phase 1, Open-label, Pilot Study to Assess the Safety, Feasibility and Initial Efficacy of IV infused Psilocin (TRP-8803)... Among Adult Patients with Binge Eating Disorder', target 12 participants, anticipated first enrolment 2025-09-01.17 Apr 2025 — Trial registered — TRP-8803 binge eating disorder study registered on ANZCTR (ACTRN12625000330448)10 Apr 2025 — Partnership — Swinburne University signs clinical trial research agreement with Tryptamine Therapeutics for IV psilocin in BED28 Jun 2024 — Trial started — First healthy-volunteer study of TRP-8803 begins enrolment (ACTRN12624000547549)
Phase change Readout Event UpcomingHover a marker for details.
Phase 1Jun 2024 – Dec 2026
  1. UpcomingCohort 2 topline (n=6, shortened 60-minute TRP-8803 infusion regimen) and final BED study results, expected by the end of calendar 2026.↗
  2. Conference presentationTwo TRP-8803 BED posters at the 39th ECNP Congress, Munich↗
  3. metCohort 1 12-week durability: all six patients kept a clinically meaningful improvement; 3/6 had no binge-eating episodes across the 84-day follow-up; weekly binge episodes 73% below baseline; anxiety -50%, depression -42%, quality of life +61%.↗
  4. PartnershipHREC approval and new Swinburne research agreement for 72-patient, eight-indication TRP-8803 basket study↗
  5. PartnershipPre-Clinical Trial Agreement with UCSF for a proposed US Phase 2 of TRP-8803 vs escitalopram in MDD↗
  6. Patent grantedSouth African patent granted for psilocybin-based treatment of fibromyalgia↗
  7. Patent grantedAustralian patent granted for psilocin crystalline forms↗
  8. metCohort 1 topline (n=6, 140-minute regimen): 100% clinically meaningful improvement (>=30% from baseline), 50% (3/6) complete remission (zero binge episodes in the 4 weeks after treatment), 74% reduction in weekly binge-eating episodes, GAD-7 -58%, PHQ-9 -57%.↗
  9. PartnershipGMP manufacturing agreement with BioCina for TRP-8803↗
  10. Corporate rebrand / name changeTryptamine Therapeutics renamed Entropy Neurodynamics; ASX code TYP becomes ENP↗
  11. First patient enrolled at Swinburne University and a 4-week baseline assessment begun. The trial will recruit 12 BED patients in two cohorts, each given two TRP-8803 doses 14 days apart with supportive therapy.↗
  12. Trial startedFirst patient enrolled in TRP-8803 binge eating disorder trial↗
  13. BED-IV study registered on ANZCTR (ACTRN12625000330448), sponsor Tryptamine Therapeutics: 'A Phase 1, Open-label, Pilot Study to Assess the Safety, Feasibility and Initial Efficacy of IV infused Psilocin (TRP-8803)... Among Adult Patients with Binge Eating Disorder', target 12 participants, anticipated first enrolment 2025-09-01.↗
  14. Trial registeredTRP-8803 binge eating disorder study registered on ANZCTR (ACTRN12625000330448)↗
  15. PartnershipSwinburne University signs clinical trial research agreement with Tryptamine Therapeutics for IV psilocin in BED↗
  16. Trial startedFirst healthy-volunteer study of TRP-8803 begins enrolment (ACTRN12624000547549)↗

TRP-8803 (IV-infused psilocin) for Binge eating disorder#

Phase 1ActiveBinge eating disorder indication →

TRP-8803 (IV-infused psilocin) with supportive psychotherapy for adults with treatment-resistant binge eating disorder (BED), the lead program of Entropy Neurodynamics. The study is run with Swinburne University of Technology and enrols two cohorts of six. The sponsor calls it Phase 2; the ANZCTR registration (ACTRN12625000330448) and the ECNP 2026 poster describe it as a Phase 1 open-label pilot. Cohort 1 patients had BED for a median of 15 years and had all failed at least one prior treatment. After two infusions on a 140-minute regimen, the sponsor reported a 100% clinically meaningful response rate and 50% clinical remission. Weekly binge-eating episodes fell 74% at four weeks and stayed 73% below baseline at 12 weeks, when three patients (50%) had had no binge episodes during the entire 84-day follow-up. Anxiety, depression and quality of life also improved. An independent Data Safety Monitoring Board endorsed progression to Cohort 2 without modifying the protocol. Cohort 2 is fully recruited and is testing a shorter 60-minute infusion. Its first patient completed treatment after the September 2026 quarter, and topline results are expected by the end of 2026. All efficacy figures are sponsor-reported from a small, uncontrolled cohort.

Readouts

  • By end of 2026 (Q4 CY2026)AnticipatedTopline data

    Cohort 2 topline (n=6, shortened 60-minute TRP-8803 infusion regimen) and final BED study results, expected by the end of calendar 2026. ↗

  • 2026-09-15ReportedInterim analysismet

    Cohort 1 12-week durability: all six patients kept a clinically meaningful improvement; 3/6 had no binge-eating episodes across the 84-day follow-up; weekly binge episodes 73% below baseline; anxiety -50%, depression -42%, quality of life +61%. ↗

  • 2026-07-07ReportedTopline datamet

    Cohort 1 topline (n=6, 140-minute regimen): 100% clinically meaningful improvement (>=30% from baseline), 50% (3/6) complete remission (zero binge episodes in the 4 weeks after treatment), 74% reduction in weekly binge-eating episodes, GAD-7 -58%, PHQ-9 -57%. ↗

Clinical trials#

ACTRN12625000330448Phase 1Activen=12

A Phase 1, Open-label, Pilot Study to Assess the Safety, Feasibility and Initial Efficacy of IV infused Psilocin (TRP-8803) Administration in Concert with Psychotherapy Among Adult Patients with Binge Eating Disorder (BED)

Started Oct 2025

ACTRN12624000547549Phase 1Completedn=9

A Phase 1, Open-label, Dose-escalation Study to Evaluate the Safety and Pharmacokinetics of a Single Intravenous Infusion of TRP-8803 (Psilocin) in Healthy Adult Participants

Started Jun 2024

ACTRN12625000403437Phase 1Unknownn=4

A Phase 1, Open-label, Single Cohort Study to Evaluate the Safety and Pharmacokinetics (PK) of a Single Intravenous (IV) Infusion of TRP-8803 [Psilocin Besylate formulation] in Healthy Adult Participants

Phase 1/2Activen=72

Phase 1b/2a open-label multi-indication basket study of TRP-8803 (IV-infused psilocin) with psychedelic-assisted psychotherapy across eight disorders (Swinburne University; HREC-approved 2026)

Conference coverage#

TRP-8803 appears in 1 CNS Pulse conference abstract:

Sources#

  1. 72 patient multi-indication trial approved to fast track TRP-8803 commercialisation (ASX, 2026-08-04) — Entropy Neurodynamics Limited (ASX: ENP)
  2. ACTRN12624000547549 - Phase 1 dose-escalation single IV infusion of TRP-8803 (Psilocin) in healthy adults (WHO ICTRP mirror of ANZCTR) — WHO International Clinical Trials Registry Platform
  3. ACTRN12624000547549 (ANZCTR record) — Australian New Zealand Clinical Trials Registry
  4. ACTRN12625000330448 - Safety, Feasibility and Initial Efficacy of IV infused Psilocin (TRP-8803) ... Adults with Binge Eating Disorder (WHO ICTRP mirror of ANZCTR) — WHO International Clinical Trials Registry Platform
  5. ACTRN12625000330448 (ANZCTR record) — Australian New Zealand Clinical Trials Registry
  6. ACTRN12625000403437 (ANZCTR record) — Australian New Zealand Clinical Trials Registry
  7. Appendix 4E and Annual Report for the year ended 30 June 2026 (ASX, 2026-08-28) — Entropy Neurodynamics Limited (ASX: ENP)
  8. Carruthers S, et al. Intravenously administered psilocin for binge eating disorder: preliminary safety and psychedelic intensity from a Phase 1 open-label trial. ECNP 2026, PS02-2061 — CNS Pulse (ECNP 2026 abstract)
  9. First patient enrolled in Binge Eating Disorder Trial (ASX release, 2025-10-14) — Tryptamine Therapeutics Limited (ASX: TYP)
  10. Quarterly Activities Report & Appendix 4C: September 2026 (ASX, 2026-10-28) — Entropy Neurodynamics Limited (ASX: ENP)
Show all 14 sources
  1. TRP-8803 clinical data presented at 39th ECNP Congress showed rapid & consistent psychedelic effects in BED patients (ASX, 2026-10-19) — Entropy Neurodynamics Limited (ASX: ENP)
  2. TRP-8803 delivers 50% remission and 100% clinically meaningful improvement in treatment-resistant BED patients (ASX, 2026-07-07) — Entropy Neurodynamics Limited (ASX: ENP)
  3. World-first intravenous psychedelic trial to treat binge eating to launch (2025-04-10) — Swinburne University of Technology
  4. World-first psilocin binge eating disorder trial reveals improvement in all patients (2026-09-15) — Swinburne University of Technology